---
title: Neoadjuvant therapy for resectable non-small cell lung cancer
date: '2024-12-06'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39642922/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20241207173203&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Treatment perspectives for non-small cell lung cancer (NSCLC) have been
  significantly expanded by the integration of immune checkpoint inhibitors into multimodal
  therapy concepts. Currently, combined, immune checkpoint-inhibitor-based therapy
  concepts are also advancing into early, resectable stages of NSCLC. Neoadjuvant
  and perioperative chemoimmunotherapy opened up a promising new preoperative treatment
  approach, but also raises some new questions and challenges. With the ...
disable_comments: true
---
Treatment perspectives for non-small cell lung cancer (NSCLC) have been significantly expanded by the integration of immune checkpoint inhibitors into multimodal therapy concepts. Currently, combined, immune checkpoint-inhibitor-based therapy concepts are also advancing into early, resectable stages of NSCLC. Neoadjuvant and perioperative chemoimmunotherapy opened up a promising new preoperative treatment approach, but also raises some new questions and challenges. With the ...